Sangamo Biosciences, Inc.
NASDAQ: SGMO
$1.11
-$0.01 (-0.9%)
Closing price June 1, 2023
Tuesday's top analyst upgrades and downgrades included American Tower, Best Buy, Dominion Energy, Intuit, NetEase, Shell, Southwest Airlines, State Street and Union Pacific.
3 months ago
Last Updated: 3 months ago
Monday's additional top analyst upgrades and downgrades included BioMarin Pharmaceutical, Micron Technology, Quanta Services, Sangamo Therapeutics, Silvergate Capital, T. Rowe Price and Zendesk.
11 months ago
Last Updated: 4 months ago
Tuesday's top analyst upgrades and downgrades included Ambarella, Annaly Capital Management, Cinedigm, Fortinet, Kinder Morgan, 3M, Nikola, Nvidia, Tesla, Uber Technologies and YETI.
2 years ago
Last Updated: 2 years ago
Many of the larger biotechnology and pharmaceutical companies have changed strategies from making acquisitions of speculative biotech outfits. In many cases it is far cheaper to just partner up with...
3 years ago
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
3 years ago
Last Updated: 3 years ago
Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer.
4 years ago
Last Updated: 3 years ago
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.
4 years ago
Last Updated: 3 years ago
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alphabet, Amarin, Apple, AutoNation, BlackRock, E*Trade, Etsy, Kellogg and PG&E.
4 years ago
Last Updated: 3 years ago
The top analyst upgrades, downgrades and initiations seen on Friday included ArcelorMittal, Barclays, Cree, Ctrip.com, Michael Kors, PVH, Skyworks Solutions, TripAdvisor, YRC Worldwide and Yelp.
4 years ago
Last Updated: 3 years ago
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
5 years ago
Last Updated: 3 years ago
Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences.
5 years ago
Last Updated: 3 years ago
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
5 years ago
Last Updated: 3 years ago
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
5 years ago
Last Updated: 3 years ago
While some of the price targets discussed here call for a stock to double, or even to rise exponentially, it is important to understand that there is a much larger risk when an analyst calls for such...
5 years ago
Last Updated: 3 years ago
Jefferies has picked out a few companies in the biotech industry that stand to win big over the coming year.
5 years ago
Last Updated: 3 years ago